A trial to evaluate SARS-CoV-2 Recombinant Nanoparticle vaccine
A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1 Adjuvant in Adult Participants 18-84 Years of Age in the U
Funder: NOVAVAX, INC.
Sponsor: NOVAVAX, INC.
CI: Professor Paul Heath
Approval Date: 28 August 2020
The aim of this study is to demonstrate the efficacy of SARS-CoV-2 rS with Matrix-M1 adjuvant in the prevention of virologically-confirmed symptomatic coronavirus disease 2019 (COVID-19), when given as a two-dose vaccination regimen, as compared to placebo, in serologically negative adults.Back to listing